AGREEMENT AND PLAN OF MERGER DATED AS OF JUNE 11, 2023, AMONG NOVARTIS AG, CHERRY MERGER SUB INC. AND CHINOOK THERAPEUTICS, INC.Merger Agreement • June 12th, 2023 • Chinook Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJune 12th, 2023 Company Industry JurisdictionThis AGREEMENT AND PLAN OF MERGER, dated as of June 11, 2023 (this “Agreement” and, such date, the “Agreement Date”), by and among Novartis AG, a company organized under the laws of Switzerland (“Parent”), Cherry Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Merger Sub”), and Chinook Therapeutics, Inc., a Delaware corporation (the “Company”). Unless expressly stated otherwise, Parent, Merger Sub and the Company are referred to in this Agreement individually as a “party” and collectively as the “parties”.
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AGAcquisition Agreement • June 12th, 2023 • Chinook Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledJune 12th, 2023 Company Industry• Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 billion